Phase I first-in-human study of TAK-285, a novel investigational dual HER2/EGFR inhibitor, in cancer patients

BACKGROUND: This phase I first-in-human study was conducted in Japanese patients to investigate the safety, pharmacokinetics (PKs), and determine the maximum tolerated dose (MTD) of oral TAK-285, a novel dual erbB protein kinase inhibitor that specifically targets human epidermal growth factor recep...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Doi, T, Takiuchi, H, Ohtsu, A, Fuse, N, Goto, M, Yoshida, M, Dote, N, Kuze, Y, Jinno, F, Fujimoto, M, Takubo, T, Nakayama, N, Tsutsumi, R
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 2012
Assuntos:
Clinical Studies
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3322948/
https://ncbi.nlm.nih.gov/pubmed/22240796
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2011.590
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados